Project Details
Description
Phase 1 First-in-Human Study of Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2) Inhibitor Monoclonal Antibody (mAb) JTX-8064, as Monotherapy and in Combination with a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, in Adult Subjects with Advanced
| Status | Active |
|---|---|
| Effective start/end date | 5/1/21 → 4/30/26 |
Funding
- JOUNCE THERAPEUTICS, INC
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.